UK markets closed

KALA BIO, Inc. (0JQ2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
6.84-0.43 (-5.88%)
At close: 04:19PM BST


1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252

Full-time employees43

Key executives

NameTitlePayExercisedYear born
Mr. Mark T. IwickiChairman & CEO1.01MN/A1966
Mr. Todd BazemorePresident & COO733.58kN/A1970
Dr. R. Kim Brazzell Ph.D.Head of R&D and Chief Medical Officer709.49kN/A1953
Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory BoardN/AN/AN/A
Ms. Mary Reumuth CPACFO & TreasurerN/AN/A1975
Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Vincent KosewskiSenior VP of Manufacturing & Supply Chain ManagementN/AN/A1963
Mr. Darius Kharabi J.D., M.B.A.Chief Business OfficerN/AN/A1979
Dr. Francis S. Mah M.D.Chief Medical AdvisorN/AN/AN/A
Mr. Josiah CraverSenior VP & Corporate ControllerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Corporate governance

KALA BIO, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.